Click here for: Upcoming New Protocols
Click here for: Current Treatment Protocols
Click here for: Recently Closed Protocols
Current Cancer Control Protocols
(New Protocols in Red)
Priority List Updated 8/30/06
Prevention
SWOG 9917 Consent HIPAA Protocol
L-Selenium-Based Chemoprevention of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia
SWOG E5597 Consent HIPAA Protocol
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
Symptom Management
Anorexia
NCCTG N02C4 Consent HIPAA Protocol
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss and Anorexia
Ascites
NCCTG N04C2 Consent HIPAA Protocol
An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide for Symptomatic Ascites in Cancer Patients
Cognitive Dysfunction
NCCTG N00C9 Consent HIPAA Protocol
The Use of Ginkgo Biloba for the Prevention of Chemotherapy-Related Cognitive Dysfunction
Hot Flashes
NCCTG N00CB Consent HIPAA Fast Facts Protocol
A Phase III Randomized, Double-Blind, Placebo-Controlled, Trial of Gabapentin in the Management of Hot Flashes in Men
Insomnia
NCCTG N01C5 Consent HIPAA Protocol
The Use of Valeriana Officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Adjuvant Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study
Neurotoxicity
NCCTG N04C7 Consent HIPAA Protocol
A Phase III Randomized, Placebo-Controlled Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity
Ovarian Function Failure
SWOG S0230 Consent HIPAA Protocol
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Vaginal Dryness
N04CA Consent HIPAA Protocol (study not yet activated)
Pilocarpine for Vaginal Dryness: A Phase III Randomized, Placebo-controlled, Double-blind Study
Hand and Foot Syndrome
A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-induced Hand and Foot Syndrome